{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:09:42Z","timestamp":1790402982605,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2005402"],"award-info":[{"award-number":["2020YFC2005402"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Research Center Projects for Geriatric Diseases","award":["NCRCG-PLAGH-2023002"],"award-info":[{"award-number":["NCRCG-PLAGH-2023002"]}]},{"name":"National Clinical Research Center Projects for Geriatric Diseases","award":["NCRCG-PLAGH-2022006"],"award-info":[{"award-number":["NCRCG-PLAGH-2022006"]}]},{"name":"Special Project for Military Healthcare Scientific Research","award":["23BJZ26"],"award-info":[{"award-number":["23BJZ26"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The concentrations of linezolid, its optimal regimen and the associated side effects in elderly patients remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicentre, prospective study, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and December 2022 were included. Linezolid concentrations and haematological toxicity were monitored dynamically. Risk factors for linezolid overexposure and moderate-to-severe linezolid-induced thrombocytopenia (M\/S LIT) were analysed, and a predictive model of M\/S LIT was developed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 860 linezolid concentrations were measured in 313 patients. The median trough concentrations of linezolid were 24.4 (15.3, 35.8) mg\/L at 36\u201372\u2005h and 26.1 (17.0, 38.1) mg\/L at 5\u201310\u2005days (P\u200a=\u200a0.132). Severe linezolid exposure was independently associated with age, estimated glomerular filtration rate (eGFR) and the worst SOFA score (SOFA1), and we further recommended dose regimens for elderly patients based on these findings. The incidences of linezolid-induced thrombocytopenia(LIT) and M\/S LIT were 73.5% and 47.6%, respectively. M\/S LIT was independently correlated with treatment duration, average trough concentration (TDMa), baseline platelet count, eGFR and baseline SOFA score (SOFA0). The developed nomogram predicted M\/S LIT with an area under the curve of 0.767 (95% CI 0.715\u20130.820), a sensitivity of 71.1% and a specificity of 73.2%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Linezolid trough concentrations increased dramatically in the elderly, by about 10\u2005mg\/L in patients aged 65\u201380\u2005years, followed by a further increase of 10\u2005mg\/L for every 10\u2005years of age. Therapeutic drug monitoring is recommended in elderly patients receiving linezolid. The developed nomogram may predict M\/S LIT and guide dosage adjustments of linezolid.<\/jats:p>\n                  <jats:p>Clinical trial registration number: ChiCTR2100045707<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae188","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:31:49Z","timestamp":1718375509000},"page":"1938-1950","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study"],"prefix":"10.1093","volume":"79","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"},{"name":"Chinese PLA Medical School , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"},{"name":"Chinese PLA Medical School , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese PLA Medical School , Beijing 100853 , China"},{"name":"Department of Pulmonary and Critical Care Medicine, The Fourth Medical Center, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jionghe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"},{"name":"Chinese PLA Medical School , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Na","sequence":"additional","affiliation":[{"name":"Chinese PLA Medical School , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[{"name":"BGI Genomics Co., Ltd , Shenzhen 518083 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiao","family":"Rao","sequence":"additional","affiliation":[{"name":"BGI Genomics Co., Ltd , Shenzhen 518083 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Fourth Medical Center, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[{"name":"College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xie","sequence":"additional","affiliation":[{"name":"College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3941-350X","authenticated-orcid":false,"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital , Beijing 100853 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"2024073123513495000_dkae188-B1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"},{"key":"2024073123513495000_dkae188-B2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2024073123513495000_dkae188-B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","article-title":"Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action?","volume":"60","author":"Cattaneo","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2024073123513495000_dkae188-B4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-017-2303-6","article-title":"Is it time to revise linezolid dose in elderly patients?","volume":"73","author":"Tinelli","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2024073123513495000_dkae188-B5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123513495000_dkae188-B6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21037\/atm.2020.03.207","article-title":"Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?\u2014experience from a prospective observational study","volume":"8","author":"Fang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2024073123513495000_dkae188-B7","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123513495000_dkae188-B8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024073123513495000_dkae188-B9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fmicb.2020.00908","article-title":"Dynamic changes of Staphylococcus aureus susceptibility to vancomycin, teicoplanin, and linezolid in a Central Teaching Hospital in Shanghai, China, 2008-2018","volume":"11","author":"Jian","year":"2020","journal-title":"Front Microbiol"},{"key":"2024073123513495000_dkae188-B10","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.2147\/IDR.S340623","article-title":"In vitro activity of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus isolates collected from Chinese Hospitals in 2018-2020","volume":"14","author":"Xu","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2024073123513495000_dkae188-B11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","article-title":"A review of population pharmacokinetic analyses of linezolid","volume":"61","author":"Band\u00edn-Vilar","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024073123513495000_dkae188-B12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","article-title":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients","volume":"22","author":"Kawasuji","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"2024073123513495000_dkae188-B13","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123513495000_dkae188-B14","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2024073123513495000_dkae188-B15","doi-asserted-by":"crossref","first-page":"117704","DOI":"10.1016\/j.cca.2023.117704","article-title":"Liquid chromatography-tandem mass spectrometry methods for quantification of total and free antibiotic concentrations in serum and exudate from patients with post-sternotomy deep sternal wound infection receiving negative pressure wound therapy","volume":"554","author":"Brozmanov\u00e1","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2024073123513495000_dkae188-B16","doi-asserted-by":"crossref","first-page":"e00687-17","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123513495000_dkae188-B17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bcp.12806","article-title":"A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?","volume":"81","author":"Pea","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2024073123513495000_dkae188-B18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024073123513495000_dkae188-B19","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2024073123513495000_dkae188-B20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123513495000_dkae188-B21","doi-asserted-by":"crossref","first-page":"106329","DOI":"10.1016\/j.ijantimicag.2021.106329","article-title":"Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"57","author":"Yeager","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123513495000_dkae188-B22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2024073123513495000_dkae188-B23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J Infect"},{"key":"2024073123513495000_dkae188-B24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2024073123513495000_dkae188-B25","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care"},{"key":"2024073123513495000_dkae188-B26","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123513495000_dkae188-B27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000445194","article-title":"Decreased linezolid serum concentrations in three critically ill patients: clinical case studies of a potential drug interaction between linezolid and rifampicin","volume":"98","author":"Blassmann","year":"2016","journal-title":"Pharmacology"},{"key":"2024073123513495000_dkae188-B28","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1128\/AAC.00757-10","article-title":"Clarithromycin significantly increases linezolid serum concentrations","volume":"54","author":"Bolhuis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123513495000_dkae188-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40780-018-0123-1","article-title":"Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies","volume":"4","author":"Hashimoto","year":"2018","journal-title":"J Pharm Health Care Sci"},{"key":"2024073123513495000_dkae188-B30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/cid\/ciac917","article-title":"Linezolid population pharmacokinetics to improve dosing in cardiosurgical patients: factoring a new drug-drug interaction pathway","volume":"76","author":"Pai","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024073123513495000_dkae188-B31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.121.000776","article-title":"Linezolid metabolism is catalyzed by cytochrome P450 2J2, 4F2, and 1B1","volume":"50","author":"Obach","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2024073123513495000_dkae188-B32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijantimicag.2019.07.021","article-title":"Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines","volume":"54","author":"Milosevic","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123513495000_dkae188-B33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.01453-12","article-title":"Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults","volume":"57","author":"Bhalodi","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1938\/58688917\/dkae188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1938\/58688917\/dkae188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:56:03Z","timestamp":1722491763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1938\/7693234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,6,14]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae188","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,6,14]]}}}